Tigerlily Foundation Celebrates FDA Approval of Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer

Approval marks an important advancement in the first-line treatment landscape and expands options for patients regardless of immunotherapy eligibility WASHINGTON, June 25, 2026 /PRNewswire/ -- Tigerlily Foundation welcomes the U.S. Food and Drug Administration's approval of Trodelvy®...